Homeindia News

    Biocon Biologics, CDSCO bribery case: CBI files charge sheet

    Biocon Biologics, CDSCO bribery case: CBI files charge sheet

    Biocon Biologics, CDSCO bribery case: CBI files charge sheet
    Read Time
    2 Min(s) Read
    Profile image

    By CNBCTV18.com  IST (Updated)

    Mini

    According to the central agency, the bribe payment of Rs 9 lakh made to Joint Drug Controller S Eswara Reddy was cleared by the associate Vice President of Biocon Biologics - L Praveen Kumar.

    The Central Bureau of Investigation (CBI) has filed a charge sheet in an alleged bribery case regarding diabetes medication clearance involving a senior official of the Central Drugs Standard Control Organisation (CDSCO) and a Biocon Biologics executive.
    According to the investigation agency, a bribe payment of Rs 9 lakh made to Joint Drug Controller S Eswara Reddy was cleared by L Praveen Kumar, the associate vice-president of Biocon Biologics.
    In June, the CBI arrested Reddy and Kumar along with Dinesh Dua, who is a director at Synergy Network India and allegedly gave the bribe to Reddy as well as assistant drug inspector Animesh Kumar.
    It was alleged that the accused tried to exert undue influence on officers of CDSCO under the Directorate General of Health Services, Ministry of Health and Family Welfare, to waive the Phase 3 trial of 'Insulin Aspart Injection'.
    Biocon Biologics in an official statement said, "It is unfortunate that parts of the charge sheet filed in the court have been leaked and some media outlets are carrying stories based on the same. Biocon has not received a copy of the chargesheet yet; hence we cannot comment further in detail."
    "We follow global best practices in regulatory science which has earned us the distinction of being the only Indian company with the largest number of regulatory approvals for Biosimilars in ICH countries like USA, Canada, EU, Japan and ANZ amongst others," it said.
    "The company has not made any payments to Bioinnovat Research or any other party named to facilitate the alleged bribe to the CDSCO official. We deny other allegations on wrong doings in seeking approval for Insulin Aspart under existing provisions and precedence. We reiterate our confidence in the judicial system and have fully cooperated with the investigating agency," the company added.
    With inputs from PTI
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    arrow down

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng